Key points from article :
Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.
Elevian develop drugs based on GDF11, a Harvard University-discovered protein linked to age-related diseases.
Injecting GDF11 into old mice regenerated cardiac, brain and muscle tissue.
It was named Science magazine's breakthrough of the year in 2014.
Financing was led by Prime Movers Lab.
Recombinant GDF11 is a novel therapy and approach to treating stroke and other age-related diseases.
"Elevian has assembled a team of excellent leaders to develop this multi-disease therapy” - Suzanne Fletcher, board member of Elevian.
“We are focused now on advancing our first drug, rGDF11 toward the clinic both to promote recovery after stroke and to treat obesity" - Mark Allen, CEO and co-founder of Elevian.
